vimarsana.com

Page 2 - இதழ் ஆஃப் தி தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NCCN Foundation Announces Awards for Rising Cancer Research Leaders

NCCN Foundation Announces Awards for Rising Cancer Research Leaders National Comprehensive Cancer Network s Oncology Research Program to oversee projects from early-career investigators advancing key areas for study in cancer care, such as cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy. News provided by Share this article ® today announced six new recipients for the 2021 NCCN Foundation  Young Investigator Awards (YIA) Program. The honorees will receive up to $150,000 in funding, over two years, to advance important research on important issues in oncology. These early-career investigators from NCCN Member Institutions represent tomorrow s leaders for advancing cancer care. The NCCN Oncology Research Program (ORP) managed the selection process and will provide guidance and oversight for the projects over the grant duration.

JNCCN Study: Important Potential Role for Routine Brain Imaging in Advanced Kidney Cancer

Share this article PLYMOUTH MEETING, Pa., April 13, 2021 /PRNewswire/  The April 2021 issue of JNCCN Journal of the National Comprehensive Cancer Network publishes new research from Memorial Sloan Kettering Cancer Center (MSK) and Gustave Roussy Institute, which suggests that baseline brain imaging should be considered in most patients with metastatic kidney cancer. The researchers studied 1,689 patients with metastatic renal cell carcinoma (mRCC) who had been considered for clinical trial participation at either of the two institutions between 2001 and 2019 and had undergone brain imaging in this context, without clinical suspicion for brain involvement. The researchers discovered 4% had asymptomatic brain metastases in this setting. This group was found to have a low median 1-year overall survival rate (48%), and median overall survival (10.3 months).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.